Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1629Carcinoma, Renal Cell 497Urinary Bladder Neoplasms 462Carcinoma, Transitional Cell 237Breast Neoplasms 227Kidney Neoplasms 215Neoplasms 193Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 171Ovarian Neoplasms 163Melanoma 163Neoplasm Metastasis 143Lung Neoplasms 130Non-Muscle Invasive Bladder Neoplasms 105Pancreatic Neoplasms 102Stomach Neoplasms 98Uterine Cervical Neoplasms 92Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 84Carcinoma, Hepatocellular 79Sarcoma 75Esophageal Neoplasms 70Head and Neck Neoplasms 69Adenocarcinoma 67Triple Negative Breast Neoplasms 65Colonic Neoplasms 53Testicular Neoplasms 52Disease 48Urologic Neoplasms 47Wilms Tumor 46

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Refractory Prostate Cancer × Genitourinary × 1 year × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡